SCD5-driven reprogramming of FA metabolism has been shown to block epithelial–mesenchymal transition, thereby reducing the probability of metastatic events and tumor malignancy in breast cancer [21] and melanoma [22,23]. The gene discussed is SCD5; the disease is breast carcinoma.